X-Seal EU Post-Market Clinical Follow-Up Protocol

Inclusion Criteria: * Candidate for non-emergent diagnostic or interventional cardiac catheterization via a femoral sheath ≤6F. * Age ≥18 years. * Understand and sign the study specific written informed consent form. * In the investigator's opinion, the patient is suitable for the X-Seal vascular closure device, conventional hemostasis techniques and participation in an investigational trial. * Eligible for sheath removal in the catheterization lab. Exclusion Criteria: * Patients who are known to be pregnant or lactating. * Patients who are immunocompromised. * Prior target artery closure with any vascular closure device or closure with manual compression win 30 days prior to this procedure. * Patients with significant anemia (hemoglobin \<10 g/DL, Hct\<30). * Patients who are morbidly obese or cachectic (BMI \>40 or \<20 kg/m2). * Patients with Systolic Blood Pressure \>180 mmHg, unless Systolic Pressure can be lowered by pharmacological agents prior to closure * Patients who are currently participating in another clinical trial of an investigational drug or device that has not concluded the follow-up period. * Patients with a baseline INR \> 1.5 (e.g. coumadin therapy). * Patients with a known bleeding disorder including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand's disease. * Patients with small femoral arteries (\<4 mm), femoral artery stenosis resulting in a vessel diameter \<4 mm, or patients with severe periphe…